(NASDAQ: SKYE) Skye Bioscience's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 69.5%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 39.87%.
Skye Bioscience's earnings in 2026 is -$51,229,330.On average, 10 Wall Street analysts forecast SKYE's earnings for 2026 to be -$34,926,604, with the lowest SKYE earnings forecast at -$44,925,326, and the highest SKYE earnings forecast at -$21,206,010. On average, 9 Wall Street analysts forecast SKYE's earnings for 2027 to be -$37,196,272, with the lowest SKYE earnings forecast at -$46,246,093, and the highest SKYE earnings forecast at -$28,274,681.
In 2028, SKYE is forecast to generate -$43,816,138 in earnings, with the lowest earnings forecast at -$49,637,773 and the highest earnings forecast at -$38,036,177.